



Ordering KRAZATI® (adagrasib)



NDC 80739-812-18: 200 mg,
bottle containing 180 tablets¹

STORAGE

Store tablets at room temperature, 20°C to 25°C (68°F to 77°F). Temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted.¹

SPECIALTY PHARMACIES AND DISTRIBUTORS

Contact one of these authorized in-network specialty pharmacies or distributors for access to KRAZATI®.

Specialty Pharmacies	Phone	Fax	URL
Biologics	800-850-4306	800-823-4506	https://biologics.mckesson.com/
Onco360 Oncology Pharmacy	877-662-6633	877-662-6355	https://www.onco360.com
Specialty Distributors	Phone	Fax	Email
Institutions/Hospitals			
ASD Specialty Healthcare	800-746-6273	800-547-9413	service@asdhealthcare.com
Cardinal Health Specialty	866-677-4844	614-553-5919	GMB-SPD-CSOrderEntry@cardinalhealth.com
McKesson Plasma & Biologics	877-625-2566	888-752-7626	mpborders@mckesson.com
Physician Dispensing Offices			
Cardinal Health Specialty	866-677-4844	614-553-5919	GMB-SPD-CSOrderEntry@cardinalhealth.com
McKesson Specialty Health	800-482-6700	855-824-9489	oncologycustomersupport@mckesson.com
Oncology Supply	800-633-7555	800-248-8205	service@oncologysupply.com

Please visit www.Krazati.com for full Prescribing Information.



Your Partner for Personalized Access and Support Resources

Start Your Patient's Journey with Assistance from a Comprehensive Support Team that Can Help Answer Questions about Coverage, Costs, and Care

The Mirati & Me Patient Support Program offers:



Coverage and Access Support

- Verify patient insurance coverage and out-of-pocket expenses for Mirati-prescribed medications
- Determine if steps are required to obtain insurance approval, such as prior authorization
- Assist with identification of the insurer's requirements for appealing a denied claim
- Identify in-network specialty pharmacy options



Financial Support*

- May provide eligible patients with assistance for paying deductibles, co-pay, and/or co-insurance for Mirati-prescribed medications[†]
- Provides assistance in the form of free product for eligible patients who do not have insurance coverage or are underinsured[‡]
- To determine if therapy is right for your patient, Mirati provides a free 30-day supply for eligible new start patients with a valid prescription. One-time offer only
- Provides assistance in the form of free product for eligible patients who experience a delay in reauthorization or a change in insurance coverage



Educational Support

Personalized education about Mirati-prescribed medications, coverage, and eligibility for programs



Emotional Support

Connects patients to independent organizations for counseling, emotional assistance, and local or online support groups



Additional Support

Refer patients to independent organizations for co-pay assistance and educational and emotional support

Visit [MiratiAndMe.com](https://www.MiratiAndMe.com) or
scan the QR code below



OR

Call 1-844-647-2842
Monday through Friday,
8 AM to 8 PM ET

*Restrictions and conditions apply.

[†]Patient must be a commercially insured U.S. or U.S. territory resident.

[‡]Annual family gross income equal to or less than \$150,000 for household size of two people; \$25,000 per additional person in household.

[§]Support options include referrals to independent nonprofit patient assistance programs. Eligibility for support provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Mirati has no control over these programs and provides referrals as a courtesy only. Educational support services are there to support, not replace, your treatment plan and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns. Terms, conditions, and program maximums apply.

Please visit www.Krazati.com for full Prescribing Information.

Reference: 1. KRAZATI. Prescribing information. Mirati Therapeutics, Inc.; 2022.

KRAZATI, Mirati, the Mirati logo, and Mirati & Me are trademarks of Mirati Therapeutics, Inc.
© 2022 Mirati Therapeutics, Inc. All rights reserved. US-KRA-22-00183 11/2022

MIRATI
THERAPEUTICS